Senti Biosciences Holdings, Inc. (SNTI)
NASDAQ: SNTI · Real-Time Price · USD
0.9522
-0.0478 (-4.78%)
May 29, 2026, 3:18 PM EDT - Market open
SNTI Revenue
Senti Biosciences Holdings had revenue of $16.00K in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $38.00K. In the year 2025, Senti Biosciences Holdings had annual revenue of $22.00K.
Revenue (ttm)
$38.00K
Revenue Growth
n/a
P/S Ratio
819.59
Revenue / Employee
$974
Employees
39
Market Cap
29.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 22.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 2.56M | -1.73M | -40.25% |
| Dec 31, 2022 | 4.29M | 1.53M | 55.23% |
| Dec 31, 2021 | 2.76M | 2.20M | 387.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Apollomics | 8.84M |
| Evaxion | 7.53M |
| ABVC BioPharma | 797.92K |
| Lisata Therapeutics | 170.00K |
| Neuphoria Therapeutics | -13.27K |
SNTI News
- 15 days ago - Senti Bio completes Type B RMAT meeting with FDA on SENTI-202 - TheFly
- 15 days ago - Senti Biosciences Holdings Earnings release: Q1 2026 - Filings
- 15 days ago - Senti Biosciences Holdings Quarterly report: Q1 2026 - Filings
- 15 days ago - Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase - GlobeNewsWire
- 15 days ago - Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program - GlobeNewsWire
- 6 weeks ago - Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026 - GlobeNewsWire
- 7 weeks ago - Senti Biosciences Holdings Slides: Corporate presentation - Filings
- 2 months ago - Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies - GlobeNewsWire